Onyx Biotec IPO
Live Updates, GMP, Subscription Data, and Financial Details
IPO Overview
Listed
Dates
Nov 13 to Nov 18 2024
Price Band
₹58 - 61
Current GMP
₹54.05 (-11.39%)
Subscription
198.00 times
IPO Details
| IPO Date | November 13, 2024 to November 18, 2024 |
| Listing Date | Friday, November 22, 2024 |
| Face Value | ₹10 per share |
| Price Band | ₹58 to ₹61 per share |
| Lot Size | 2000 Shares |
| Total Issue Size | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Fresh Issue | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 13,322,200 |
| Share holding post issue | 18,132,200 |
| Market Maker portion | 244,000 shares Giriraj Stock Broking |
IPO Date
November 13, 2024 to November 18, 2024
Listing Date
Friday, November 22, 2024
Face Value
₹10 per share
Price Band
₹58 to ₹61 per share
Lot Size
2000 Shares
Total Issue Size
4,810,000 shares (aggregating up to ₹29.34 Cr)
Fresh Issue
4,810,000 shares (aggregating up to ₹29.34 Cr)
Issue Type
Book Built Issue IPO
Listing At
NSE SME
Share holding pre issue
13,322,200
Share holding post issue
18,132,200
Market Maker portion
244,000 shares Giriraj Stock Broking
IPO Subscription Details
| Anchor Investors | 1 |
| Market Maker | 1 |
| Qualified Institutions | 32.49 |
| Non-Institutional Buyers*** | 602.86 |
| Retail Investors | 118.26 |
| Total ** | 198.00 |
Anchor Investors
1
Market Maker
1
Qualified Institutions
32.49
Non-Institutional Buyers***
602.86
Retail Investors
118.26
Total **
198.00
Day Wise Sub
| Day | QIB | NII* | Retail | Total |
|---|---|---|---|---|
| Day 1 Nov 13, 2024 | 0.00 | 1.70 | 5.57 | 3.15 |
| Day 2 Nov 14, 2024 | 0.00 | 8.15 | 16.40 | 9.95 |
| Day 3 Nov 18, 2024 | 32.49 | 602.86 | 118.26 | 198.00 |
DayDay 1
Nov 13, 2024
QIB0.00
NII*1.70
Retail5.57
Total3.15
DayDay 2
Nov 14, 2024
QIB0.00
NII*8.15
Retail16.40
Total9.95
DayDay 3
Nov 18, 2024
QIB32.49
NII*602.86
Retail118.26
Total198.00
Day Wise GMP
| Date | Price | GMP | Estimate List Price |
|---|---|---|---|
| 22-11-2024 | 61.00 | 5(8.2%) | 66 |
| 21-11-2024 | 61.00 | 5(8.2%) | 66 |
| 20-11-2024 | 61.00 | 6(9.84%) | 67 |
| 19-11-2024 | 61.00 | 6(9.84%) | 67 |
| 18-11-2024 | 61.00 | 10(16.39%) | 71 |
| 17-11-2024 | 61.00 | 15(24.59%) | 76 |
| 16-11-2024 | 61.00 | 15(24.59%) | 76 |
| 15-11-2024 | 61.00 | 15(24.59%) | 76 |
| 14-11-2024 | 61.00 | 15(24.59%) | 76 |
| 13-11-2024 | 61.00 | 15(24.59%) | 76 |
| 12-11-2024 | 61.00 | 10(16.39%) | 71 |
| 11-11-2024 | 61.00 | 10(16.39%) | 71 |
| 10-11-2024 | 61.00 | 5(8.2%) | 66 |
| 09-11-2024 | 61.00 | 5(8.2%) | 66 |
| 08-11-2024 | 61.00 | 5(8.2%) | 66 |
| 07-11-2024 | 61.00 | 0(0%) | (0%) |
Date22-11-2024
Price61.00
GMP5(8.2%)
Estimate List Price66
Date21-11-2024
Price61.00
GMP5(8.2%)
Estimate List Price66
Date20-11-2024
Price61.00
GMP6(9.84%)
Estimate List Price67
Date19-11-2024
Price61.00
GMP6(9.84%)
Estimate List Price67
Date18-11-2024
Price61.00
GMP10(16.39%)
Estimate List Price71
Date17-11-2024
Price61.00
GMP15(24.59%)
Estimate List Price76
Date16-11-2024
Price61.00
GMP15(24.59%)
Estimate List Price76
Date15-11-2024
Price61.00
GMP15(24.59%)
Estimate List Price76
Date14-11-2024
Price61.00
GMP15(24.59%)
Estimate List Price76
Date13-11-2024
Price61.00
GMP15(24.59%)
Estimate List Price76
Date12-11-2024
Price61.00
GMP10(16.39%)
Estimate List Price71
Date11-11-2024
Price61.00
GMP10(16.39%)
Estimate List Price71
Date10-11-2024
Price61.00
GMP5(8.2%)
Estimate List Price66
Date09-11-2024
Price61.00
GMP5(8.2%)
Estimate List Price66
Date08-11-2024
Price61.00
GMP5(8.2%)
Estimate List Price66
Date07-11-2024
Price61.00
GMP0(0%)
Estimate List Price(0%)
IPO Important Dates
| IPO Open Date | Wednesday, November 13, 2024 |
| IPO Close Date | Monday, November 18, 2024 |
| Basis of Allotment | Tuesday, November 19, 2024 |
| Initiation of Refunds | Wednesday, November 20, 2024 |
| Credit of Shares to Demat | Wednesday, November 20, 2024 |
| Listing Date | Friday, November 22, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on November 18, 2024 |
IPO Open Date
Wednesday, November 13, 2024
IPO Close Date
Monday, November 18, 2024
Basis of Allotment
Tuesday, November 19, 2024
Initiation of Refunds
Wednesday, November 20, 2024
Credit of Shares to Demat
Wednesday, November 20, 2024
Listing Date
Friday, November 22, 2024
Cut-off time for UPI mandate confirmation
5 PM on November 18, 2024
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2000 | ₹122,000 |
| Retail (Max) | 1 | 2000 | ₹122,000 |
| HNI (Min) | 2 | 4,000 | ₹244,000 |
ApplicationRetail (Min)
Lots1
Shares2000
Amount₹122,000
ApplicationRetail (Max)
Lots1
Shares2000
Amount₹122,000
ApplicationHNI (Min)
Lots2
Shares4,000
Amount₹244,000
Financial Information
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 7,476.57 | 7,413.58 | 5,872.36 |
| Revenue | 1,054.11 | 5,387.43 | 3,961.65 |
| Profit After Tax | 130.77 | 303.16 | 184.46 |
| Net Worth | 2,618.64 | 2,487.87 | 1,820.16 |
| Reserves and Surplus | 1,286.42 | 1,155.65 | 1,230.00 |
| Total Borrowing | 3,156.14 | 3,078.04 | 2,922.83 |
Period EndedPeriod Ended
31 May 202431 May 2024
31 Mar 202431 Mar 2024
31 Mar 202331 Mar 2023
Period EndedAssets
31 May 20247,476.57
31 Mar 20247,413.58
31 Mar 20235,872.36
Period EndedRevenue
31 May 20241,054.11
31 Mar 20245,387.43
31 Mar 20233,961.65
Period EndedProfit After Tax
31 May 2024130.77
31 Mar 2024303.16
31 Mar 2023184.46
Period EndedNet Worth
31 May 20242,618.64
31 Mar 20242,487.87
31 Mar 20231,820.16
Period EndedReserves and Surplus
31 May 20241,286.42
31 Mar 20241,155.65
31 Mar 20231,230.00
Period EndedTotal Borrowing
31 May 20243,156.14
31 Mar 20243,078.04
31 Mar 20232,922.83
Key Performance Indicator
| ROE | 4.99% |
| ROCE | 3.71% |
| Debt/Equity | 1.21 |
| RoNW | 4.99% |
| P/BV | 3.1 |
| PAT Margin (%) | 12.42 |
| EPS (Rs) | 2.28 |
ROE
4.99%
ROCE
3.71%
Debt/Equity
1.21
RoNW
4.99%
P/BV
3.1
PAT Margin (%)
12.42
EPS (Rs)
2.28
IPO Reservation
| Anchor Investor Shares Offered | 13,66,000 (28.4%) |
| Market Maker Shares Offered | 2,44,000 (5.07%) |
| QIB Shares Offered | 9,12,000 (18.96%) |
| NII (HNI) Shares Offered | 6,88,000 (14.3%) |
| Retail Shares Offered | 16,00,000 (33.26%) |
| Total Shares Offered | 48,10,000 (100%) |
Anchor Investor Shares Offered
13,66,000 (28.4%)
Market Maker Shares Offered
2,44,000 (5.07%)
QIB Shares Offered
9,12,000 (18.96%)
NII (HNI) Shares Offered
6,88,000 (14.3%)
Retail Shares Offered
16,00,000 (33.26%)
Total Shares Offered
48,10,000 (100%)
Information about company
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.
The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.
The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.
As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.
The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.
As of July 31, 2024, the company has 175 employees across various departments.
Objectives of IPO
The Company proposes to utilize the Net Proceeds from the Issue towards the following objects:
Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use;
Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;
Prepayment or repayment of all or a portion of certain loans availed by the Company; and
General Corporate Purposes.
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App